Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, and Phase 2.
The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab
vedotin to patients with AML. The goal of Phase 1 is to learn more about the safety of the
combination of brentuximab vedotin with azacytidine. The goal of Phase 2 is to learn if the
combination of brentuximab vedotin and azacytidine can help to control AML.